Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
Vertex Pharmaceuticals (VRTX) has recently gained attention due to positive clinical data and earnings revisions, alongside concerns over its valuation. Analysts project earnings of $5.00 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback